Clinical characterization of HCC/CCA mixed cancers in a population-based cohort

• Verfasst von: Teufel, Andreas [VerfasserIn]
• Verfasst von: Rodriguez, Isaac [VerfasserIn]
• Verfasst von: Winzler, Claudia [VerfasserIn]
• Verfasst von: Kokh, Daria [VerfasserIn]
• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Surovtsova, Irina [VerfasserIn]
• Verfasst von: Morakis, Philipp [VerfasserIn]
• Titel: Clinical characterization of HCC/CCA mixed cancers in a population-based cohort
• Titelzusatz: original article
• Verf.angabe: Andreas Teufel, Isaac Rodriguez, Claudia Winzler, Daria Kokh, Matthias P. Ebert, Irina Surovtsova, Philipp Morakis
• E-Jahr: 2023
• Jahr: June 2023
• Umfang: 7 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 24.07.2024
• Titel Quelle: Enthalten in: Journal of gastrointestinal and liver diseases
• Ort Quelle: Cluj-Napoca : Soc., 2006
• Jahr Quelle: 2023
• Band/Heft Quelle: 32(2023), 2 vom: Juni, Seite 190-196
• ISSN Quelle: 1842-1121
• DOI: doi:10.15403/jgld-4893
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: combined hepatocellular cholangiocarcinoma
• Sach-SW: hepatocellular carcinoma
• Sach-SW: histological diagnosis
• Sach-SW: intrahepatic cholangiocarcinoma
• Sach-SW: survival
• K10plus-PPN: 1896189105

Abstract

Background and Aims: Primary liver cancer (PLC) ranks among of the most common cancers worldwide. Within this group, a minority of cases displays characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), known as combined hepatocellular cholangiocarcinoma (cHCC- CCA). Currently, there is no specific standardized therapy for these mixed tumors. Therefore, the aim of our study was to analyze the clinical course, treatment and outcome of cHCC-CCA patients in a European population-based registry. - Methods: We investigated 9,144 patients with PLC (6,622 HCC, 2,356 iCCA, and 166 cHCC-CCA) diagnosed between 2009 and 2020. All data were obtained from Clinical Cancer Registry of Baden-Württemberg (BW), Germany. - Results: In all three groups patients were predominantly male (82%, 57%, and 68% for HCC, iCCA and cHCC-CCA groups, respectively). 48% of cHCC-CCA patients were diagnosed as stage IV cancers, which was more than for HCC (31%) but less compared to CCA (64%). Overall median survival of cHCC-CCA patients was worse compared to HCC (9-13 months vs. 15.5 months, p<0.001) and rather comparable to CCA (11.8 months). - Conclusions: Our data demonstrated that cHCC-CCA tumors appear to have a distinct clinical course with worse overall survival compared to HCC. Thus, identification of these cancers by histopathology is essential in order to further characterize this tumor entity and to provide accurate treatment to these patients.